An oral HIV drug helped patients with center-involved diabetic macular edema achieve improvements in visual acuity, according ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The 5th Eye Care Summit for the Middle East, Africa, and Russia (MEAR) region, under the patronage of AbbVie, the global ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

ANI’s FutureVision Advisory Council is co-led by Arshad M. Khanani, MD, MA, FASRS, who serves as Principal Retina Advisor and Chair, and Peter Chang, MD, FACS who serves as Principal Uveitis Advisor ...

Thomas A. Barnard, MD; S.K. Steven Houston, MD, FASRS; Thalmon R. Campagnoli, MD; Raul J. Moreno, MD; Jonathan A. Staman, MD; ...

On the innovative side, there are ongoing trials for combining therapies—anti-VEGF plus steroids or laser—to get better and faster outcomes. AI-assisted retina exams are enabling doctors to detect DME ...

High blood pressure silently damages delicate eye blood vessels, potentially leading to vision loss. Early warning signs like blurry vision or bleeding can be detected during eye exams, even before ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Ruiz, an internationally recognized ophthalmologist and experienced drug development leader, has joined the company as Chief ...